SOFTX SoftOx Solutions AS
SoftOx Solutions AS, together with its subsidiaries, operates as a clinical-stage pharmaceutical company that anti-infective therapy for airway infections in Norway. The company develops SIS-03, a lead clinical program that is in phase 2a to treatment of chronic airway infections. It also developing pan antimicrobial pharmaceuticals targeting bacteria, viruses, yeast, spores, and fungi. SoftOx Solutions AS was founded in 2012 and is based in Lysaker, Norway.…
Industry Peers
BiotechnologyKey Statistics
About SoftOx Solutions (OSL: SOFTX)
›
SoftOx Solutions (OSL: SOFTX) is listed on Oslo Børs, where its shares trade in NOK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 2 employees.
The shares were at 0.1062 NOK on 19 November 2026, up 51.3% over 52 weeks. Its 52-week range is 0.0490 NOK to 0.1658 NOK: the price is 35.9% below the high and 116.7% above the low.
Its market capitalisation is 287.75M NOK.
SoftOx Solutions reports return on equity of -47.1%, an operating margin of -165.9% and revenue down 55.6% year over year.
It holds more cash than debt, a net cash position of 21.37M NOK. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.